Roic AI
Search
/
Search
/
Pricing
Sign inSign up

You're using the beta version. You're using the beta version of the new website.

SummaryFinancialsRatiosTranscriptsClassic View

Footer

Found an error or have an idea?
or write us an email to [email protected]

Company

  • About
  • Pricing
  • Blog

Support

  • Knowledge Base
  • FAQ

Legal

  • Privacy Policy

© 2023 Roic AI, Inc. All rights reserved.

  1. United States Stocks
  2. •

    Healthcare
  3. •

    Biotechnology
Innoviva, Inc. logo

Innoviva, Inc.

HVE GR

HVE GRInnoviva, Inc.GRGR
FIGI: BBG000FQTHC3

Company Description

Full Time Employees
101
Sector
Healthcare
Industry
Biotechnology
Address
1350 Old Bayshore Highway Burlingame CA United States 94010
CIK
0001080014
Website
www.inva.com
Business
Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

12.00

EUR
-0.10
(-0.83%)

Company News

  • Dow Jones Newswires

    a month ago

    Innoviva Appoints Stephen Basso As Chief Financial Officer >INVA

  • Dow Jones Newswires

    2 months ago

    Innoviva 2Q EPS 2c >INVA

  • MarketWatch.com

    4 months ago

    FDA approves Innoviva's bacterial pneumonia treatment

  • Dow Jones Newswires

    5 months ago

    Innoviva 1Q EPS 42c >INVA

  • Dow Jones Newswires

    5 months ago

    Innoviva Announces Retirement Of Board Chairman >INVA

  • Dow Jones Newswires

    5 months ago

    Innoviva Shares Rise 7% After Pneumonia Drug's Approval by FDA Committee

  • Dow Jones Newswires

    5 months ago

    Innoviva Shares Halted as FDA Panel Reviews Sulbactam-Durlobactam >INVA

  • Barron's

    2 years ago

    Theravance Stock Drops on Covid-19 Therapy Disappointment

Next Earnings
November 7
Ex-Dividend Date
September 8
Dividend Date
September 30
Held by Insiders
1.34%
Held by Institutions
110.39%
Short % of Float
13.15%
YTD Yield
1.68%
3Y Yield
32.24%
Working Capital
USD

•

in mil. unless spec.
Dec'22
Mar'23
Jun'23
Total Current Assets
444
296
324
Cash, Cash Equivalents & STI
291
144
173
Accounts Receivable, Net
64
76
81
Inventories
56
50
47
Total Current Liabilities
39
38
39
Payables & Accruals
4
1
31
ST Debt
98
1
1
Deferred Revenue
2
2
3
Capital Structure
USD

•

in mil. unless spec.
Dec'22
Mar'23
Jun'23
ST Debt
98
1
1
LT Borrowings
540
445
445
LT Finance Leases
2
2
2
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
69
66
65
Market Capitalization
917
741
830
Quarterly Revenue
USD

•

in mil. unless spec.
Year
Q1
Q2
Q3
Q4
FY
2021
86
101
98
108
392
2022
90
108
67
66
331
2023
76
81
- -
- -
- -
Growth Rates
USD

•

in mil. unless spec.
(avg. rate of change)
10 years
5 years
1 year
Sales/Revenue/Turnover
79.89%
10.03%
-15.56%
Net Income, GAAP
-82.56%
35.28%
-19.55%
Free Cash Flow
57.50%
13.18%
-44.35%
Total Cash Common Dividend
- -
- -
- -
Total Equity
-8.57%
4.31%
7.60%
Quarterly Dividends Per Share
USD

•

in mil. unless spec.
Year
Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
Quarterly Earnings Per Share
USD

•

in mil. unless spec.
Year
Q1
Q2
Q3
Q4
FY
2021
0.93
1.01
1.04
0.15
3.24
2022
0.23
0.01
3.81
-0.98
3.07
2023
0.51
0.02
- -
- -
- -